{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:15:48Z","timestamp":1791310548366,"version":"4.3.1"},"reference-count":83,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2015.0837","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T05:24:09Z","timestamp":1525238649000},"source":"Crossref","is-referenced-by-count":49,"title":["Urosepsis\u2014Etiology, Diagnosis, and Treatment"],"prefix":"10.3238","author":[{"given":"Nici Markus","family":"Dreger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Degener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parviz","family":"Ahmad-Nejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"W\u00f6bker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2015,12,4]]},"reference":[{"key":"10.3238\/arztebl.2015.0837_ref1","doi-asserted-by":"crossref","unstructured":"Rivers E, Nguyen B, Havstad S, et al.: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368\u201377","DOI":"10.1056\/NEJMoa010307"},{"key":"10.3238\/arztebl.2015.0837_ref2","unstructured":"Reinhart K, Brunkhorst FM, Bone HG, et al.: Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e. V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinare Vereinigung fur Intensiv- und Notfallmedizin (DIVI)). Ger Med Sci 2010; 8: Doc14"},{"key":"10.3238\/arztebl.2015.0837_ref3","doi-asserted-by":"crossref","unstructured":"Levy MM, Artigas A, Phillips GS, et al.: Outcomes of the surviving sepsis campaign in intensive care units in the USA and Europe: a prospective cohort study. Lancet Infect Dis 2012; 12: 919\u201324","DOI":"10.1016\/S1473-3099(12)70239-6"},{"key":"10.3238\/arztebl.2015.0837_ref4","doi-asserted-by":"crossref","unstructured":"Dellinger RP, Levy MM, Rhodes A, et al.: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39: 165\u2013228","DOI":"10.1007\/s00134-012-2769-8"},{"key":"10.3238\/arztebl.2015.0837_ref5","unstructured":"Grabe M, Bartoletti R, Bjerklund Johansen TE, et al.: Urological infections. European Association of Urology Guidelines: Elsevier 2015: 641\u20136."},{"key":"10.3238\/arztebl.2015.0837_ref6","doi-asserted-by":"crossref","unstructured":"Bone RC, Balk RA, Cerra FB, et al.: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP\/SCCM Consensus Conference Committee. American College of Chest Physicians\/Society of Critical Care Medicine. Chest 1992; 101: 1644\u201355","DOI":"10.1378\/chest.101.6.1644"},{"key":"10.3238\/arztebl.2015.0837_ref7","doi-asserted-by":"crossref","unstructured":"Levy MM, Fink MP, Marshall JC, et al.: 2001 SCCM\/ESICM\/ACCP\/ATS\/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250\u20136","DOI":"10.1097\/01.CCM.0000050454.01978.3B"},{"key":"10.3238\/arztebl.2015.0837_ref8","doi-asserted-by":"crossref","unstructured":"Engel C, Brunkhorst FM, Bone HG, et al.: Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 2007; 33: 606\u201318","DOI":"10.1007\/s00134-006-0517-7"},{"key":"10.3238\/arztebl.2015.0837_ref9","doi-asserted-by":"crossref","unstructured":"Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546\u201354","DOI":"10.1056\/NEJMoa022139"},{"key":"10.3238\/arztebl.2015.0837_ref10","doi-asserted-by":"crossref","unstructured":"Wagenlehner FM, Lichtenstern C, Rolfes C, et al.: Diagnosis and management for urosepsis. Int J Urol 2013; 20: 963\u201370","DOI":"10.1111\/iju.12200"},{"key":"10.3238\/arztebl.2015.0837_ref11","doi-asserted-by":"crossref","unstructured":"Brun-Buisson C, Meshaka P, Pinton P, Vallet B, Group ES: EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004; 30: 580\u20138","DOI":"10.1007\/s00134-003-2121-4"},{"key":"10.3238\/arztebl.2015.0837_ref12","doi-asserted-by":"crossref","unstructured":"Brunkhorst FM: [Epidemiology, economy and practice\u2013results of the German study on prevalence by the competence network sepsis (SepNet)]. Anasthesiol Intensivmed Notfallmed Schmerzther 2006; 41: 43\u20134","DOI":"10.1055\/s-2005-921227"},{"key":"10.3238\/arztebl.2015.0837_ref13","doi-asserted-by":"crossref","unstructured":"Moerer O, Schmid A, Hofmann M, et al.: Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use. Intensive Care Med 2002; 28: 1440\u20136","DOI":"10.1007\/s00134-002-1429-9"},{"key":"10.3238\/arztebl.2015.0837_ref14","doi-asserted-by":"crossref","unstructured":"Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138\u201350","DOI":"10.1056\/NEJMra021333"},{"key":"10.3238\/arztebl.2015.0837_ref15","doi-asserted-by":"crossref","unstructured":"Astiz ME, Rackow EC: Septic shock. Lancet 1998; 351: 1501\u20135","DOI":"10.1016\/S0140-6736(98)01134-9"},{"key":"10.3238\/arztebl.2015.0837_ref16","doi-asserted-by":"crossref","unstructured":"Mariappan P, Loong CW: Midstream urine culture and sensitivity test is a poor predictor of infected urine proximal to the obstructing ureteral stone or infected stones: a prospective clinical study. J Urol 2004; 171: 2142\u20135","DOI":"10.1097\/01.ju.0000125116.62631.d2"},{"key":"10.3238\/arztebl.2015.0837_ref17","doi-asserted-by":"crossref","unstructured":"Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlini A: Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med 2003; 31: 1737\u201341","DOI":"10.1097\/01.CCM.0000063440.19188.ED"},{"key":"10.3238\/arztebl.2015.0837_ref18","doi-asserted-by":"crossref","unstructured":"Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J: Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39: 206\u201317","DOI":"10.1086\/421997"},{"key":"10.3238\/arztebl.2015.0837_ref19","doi-asserted-by":"crossref","unstructured":"Brunkhorst FM, Wegscheider K, Forycki ZF, Brunkhorst R: Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med 2000; 26 (Suppl 2): 148\u201352","DOI":"10.1007\/s001340051134"},{"key":"10.3238\/arztebl.2015.0837_ref20","doi-asserted-by":"crossref","unstructured":"van Nieuwkoop C, Bonten TN, van't Wout JW, et al.: Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study. Crit Care 2010; 14: R206","DOI":"10.1186\/cc9328"},{"key":"10.3238\/arztebl.2015.0837_ref21","doi-asserted-by":"crossref","unstructured":"Schuetz P, Christ-Crain M, Thomann R, et al.: Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302: 1059\u201366","DOI":"10.1001\/jama.2009.1297"},{"key":"10.3238\/arztebl.2015.0837_ref22","doi-asserted-by":"crossref","unstructured":"Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J: Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008; 177: 498\u2013505","DOI":"10.1164\/rccm.200708-1238OC"},{"key":"10.3238\/arztebl.2015.0837_ref23","doi-asserted-by":"crossref","unstructured":"Heyland DK, Johnson AP, Reynolds SC, Muscedere J: Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med 2011; 39: 1792\u20139","DOI":"10.1097\/CCM.0b013e31821201a5"},{"key":"10.3238\/arztebl.2015.0837_ref24","doi-asserted-by":"crossref","unstructured":"Kumar A, Ellis P, Arabi Y, et al.: Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136: 1237\u201348","DOI":"10.1378\/chest.09-0087"},{"key":"10.3238\/arztebl.2015.0837_ref25","doi-asserted-by":"crossref","unstructured":"Kumar A, Roberts D, Wood KE, et al.: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589\u201396","DOI":"10.1097\/01.CCM.0000217961.75225.E9"},{"key":"10.3238\/arztebl.2015.0837_ref26","doi-asserted-by":"crossref","unstructured":"Mouncey PR, Osborn TM, Power GS, et al.: Trial of early, goal-directed resuscitation for septic shock. N Engl J Med 2015; 372: 1301\u201311","DOI":"10.1056\/NEJMoa1500896"},{"key":"10.3238\/arztebl.2015.0837_ref27","doi-asserted-by":"crossref","unstructured":"Pro CI, Yealy DM, Kellum JA, et al.: A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014; 370: 1683\u201393","DOI":"10.1056\/NEJMoa1401602"},{"key":"10.3238\/arztebl.2015.0837_ref28","doi-asserted-by":"crossref","unstructured":"Investigators A, Group ACT, Peake SL, et al.: Goal-directed resuscitation for patients with early septic shock. N Engl J Med 2014; 371: 1496\u2013506","DOI":"10.1056\/NEJMoa1404380"},{"key":"10.3238\/arztebl.2015.0837_ref29","doi-asserted-by":"crossref","unstructured":"Ramsey S, Robertson A, Ablett MJ, Meddings RN, Hollins GW, Little B: Evidence-based drainage of infected hydronephrosis secondary to ureteric calculi. J Endourol 2010; 24: 185\u20139","DOI":"10.1089\/end.2009.0361"},{"key":"10.3238\/arztebl.2015.0837_ref30","doi-asserted-by":"crossref","unstructured":"Brunkhorst FM, Engel C, Bloos F, et al.: Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358: 125\u201339","DOI":"10.1056\/NEJMoa070716"},{"key":"10.3238\/arztebl.2015.0837_ref31","doi-asserted-by":"crossref","unstructured":"Guidet B, Martinet O, Boulain T, et al.: Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130\/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study. Crit Care 2012; 16: R94","DOI":"10.1186\/cc11358"},{"key":"10.3238\/arztebl.2015.0837_ref32","doi-asserted-by":"crossref","unstructured":"Myburgh JA, Finfer S, Bellomo R, et al.: Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012; 367: 1901\u201311","DOI":"10.1056\/NEJMoa1209759"},{"key":"10.3238\/arztebl.2015.0837_ref33","doi-asserted-by":"crossref","unstructured":"Perner A, Haase N, Guttormsen AB, et al.: Hydroxyethyl starch 130\/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012; 367: 124\u201334","DOI":"10.1056\/NEJMoa1204242"},{"key":"10.3238\/arztebl.2015.0837_ref34","doi-asserted-by":"crossref","unstructured":"Martin C, Viviand X, Leone M, Thirion X: Effect of norepinephrine on the outcome of septic shock. Crit Care Med 2000; 28: 2758\u201365","DOI":"10.1097\/00003246-200008000-00012"},{"key":"10.3238\/arztebl.2015.0837_ref35","unstructured":"Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J: Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000; 356: 2139\u201343"},{"key":"10.3238\/arztebl.2015.0837_ref36","doi-asserted-by":"crossref","unstructured":"Sprung CL, Annane D, Keh D, et al.: Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358: 111\u201324","DOI":"10.1056\/NEJMoa071366"},{"key":"10.3238\/arztebl.2015.0837_ref37","doi-asserted-by":"crossref","unstructured":"Investigators N-SS, Finfer S, Chittock DR, et al.: Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283\u201397","DOI":"10.1056\/NEJMoa0810625"},{"key":"10.3238\/arztebl.2015.0837_ref38","doi-asserted-by":"crossref","unstructured":"Martin GS, Mannino DM, Moss M: The effect of age on the development and outcome of adult sepsis. Crit Care Med 2006; 34: 15\u201321","DOI":"10.1097\/01.CCM.0000194535.82812.BA"},{"key":"10.3238\/arztebl.2015.0837_ref39","doi-asserted-by":"crossref","unstructured":"Bjerklund Johansen TE, Cek M, Naber K, et al.: Prevalence of hospital-acquired urinary tract infections in urology departments. Eur Urol 2007; 51: 1100\u201311; discussion 12","DOI":"10.1016\/j.eururo.2006.08.012"},{"key":"10.3238\/arztebl.2015.0837_ref40","doi-asserted-by":"crossref","unstructured":"Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO: Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 2015; 385: 1949\u201356","DOI":"10.1016\/S0140-6736(14)62220-0"},{"key":"10.3238\/arztebl.2015.0837_ref41","doi-asserted-by":"crossref","unstructured":"Moerer O, Quintel M: [Sepsis in adult patients \u2013 definitions, epidemiology and economic aspects]. Der Internist 2009; 50: 788, 90\u20134, 96\u20138.","DOI":"10.1007\/s00108-008-2285-7"},{"key":"10.3238\/arztebl.2015.0837_ref42","doi-asserted-by":"crossref","unstructured":"Mehta RL, Kellum JA, Shah SV, et al.: Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31.","DOI":"10.1186\/cc5713"},{"key":"10.3238\/arztebl.2015.0837_ref43","doi-asserted-by":"crossref","unstructured":"Angus DC: The lingering consequences of sepsis: a hidden public health disaster? JAMA 2010; 304: 1833\u20134","DOI":"10.1001\/jama.2010.1546"},{"key":"10.3238\/arztebl.2015.0837_ref44","doi-asserted-by":"crossref","unstructured":"Moerer O, Burchardi H: [The cost of sepsis]. Anaesthesist 2006; 55 (Suppl 1): 36\u201342.","DOI":"10.1007\/s00101-006-1039-y"},{"key":"10.3238\/arztebl.2015.0837_ref45","doi-asserted-by":"crossref","unstructured":"Schmid A, Burchardi H, Clouth J, Schneider H: Burden of illness imposed by severe sepsis in Germany. Eur J Health Econ: HEPAC : health economics in prevention and care 2002; 3: 77\u201382","DOI":"10.1007\/s10198-002-0095-8"},{"key":"10.3238\/arztebl.2015.0837_ref46","doi-asserted-by":"crossref","unstructured":"Schiefer HG: Urosepsis. In: Schmelz H, Sparwasser C, Weidner W, (eds.): Facharztwissen Urologie. Heidelberg: SpringerMedizin 2014; 51\u20137.","DOI":"10.1007\/978-3-662-45739-9_5"},{"key":"10.3238\/arztebl.2015.0837_ref47","unstructured":"Hofmann W: [Urosepsis and uroseptic shock]. Z Urol Nephrol 1990; 83: 317\u201324."},{"key":"10.3238\/arztebl.2015.0837_ref48","unstructured":"Serniak PS, Denisov VK, Guba GB, et al.: [The diagnosis of urosepsis]. Urol Nefrol (Mosk) 1990: 9\u201313."},{"key":"10.3238\/arztebl.2015.0837_ref49","doi-asserted-by":"crossref","unstructured":"Stehr SN, Woest I, Hartog CS, Reinhart K: [Sepsis: putting knowledge into practice]. Der Internist 2013; 54: 63\u201372; quiz 3\u20134.","DOI":"10.1007\/s00108-012-3192-5"},{"key":"10.3238\/arztebl.2015.0837_ref50","doi-asserted-by":"crossref","unstructured":"Rittirsch D, Flierl MA, Ward PA: Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008; 8: 776\u201387","DOI":"10.1038\/nri2402"},{"key":"10.3238\/arztebl.2015.0837_ref51","doi-asserted-by":"crossref","unstructured":"Hacker H, Vabulas RM, Takeuchi O, Hoshino K, Akira S, Wagner H: Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med 2000; 192: 595\u2013600","DOI":"10.1084\/jem.192.4.595"},{"key":"10.3238\/arztebl.2015.0837_ref52","doi-asserted-by":"crossref","unstructured":"Medzhitov R, Preston-Hurlburt P, Kopp E, et al.: MyD88 is an adaptor protein in the hToll\/IL-1 receptor family signaling pathways. Mol Cell 1998; 2: 253\u20138","DOI":"10.1016\/S1097-2765(00)80136-7"},{"key":"10.3238\/arztebl.2015.0837_ref53","doi-asserted-by":"crossref","unstructured":"Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z: MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 1997; 7: 837\u201347","DOI":"10.1016\/S1074-7613(00)80402-1"},{"key":"10.3238\/arztebl.2015.0837_ref54","doi-asserted-by":"crossref","unstructured":"Takeuchi O, Hoshino K, Kawai T, et al.: Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999; 11: 443\u201351","DOI":"10.1016\/S1074-7613(00)80119-3"},{"key":"10.3238\/arztebl.2015.0837_ref55","doi-asserted-by":"crossref","unstructured":"Wagenlehner FM, Lichtenstern C, Weigand MA, Weidner W: [Urosepsis and treatment]. Urologe A 2010; 49: 618\u201322.","DOI":"10.1007\/s00120-010-2253-4"},{"key":"10.3238\/arztebl.2015.0837_ref56","doi-asserted-by":"crossref","unstructured":"Chen YX, Li CS: Risk stratification and prognostic performance of the predisposition, infection, response, and organ dysfunction (PIRO) scoring system in septic patients in the emergency department: a cohort study. Crit Care 2014; 18: R74","DOI":"10.1186\/cc13832"},{"key":"10.3238\/arztebl.2015.0837_ref57","doi-asserted-by":"crossref","unstructured":"Reimer LG, Wilson ML, Weinstein MP: Update on detection of bacteremia and fungemia. Clin Microbiol Rev 1997; 10: 444\u201365.","DOI":"10.1128\/CMR.10.3.444"},{"key":"10.3238\/arztebl.2015.0837_ref58","doi-asserted-by":"crossref","unstructured":"Cockerill FR, 3rd, Wilson JW, Vetter EA, et al.: Optimal testing parameters for blood cultures. Clin Infect Dis 2004; 38: 1724\u201330","DOI":"10.1086\/421087"},{"key":"10.3238\/arztebl.2015.0837_ref59","doi-asserted-by":"crossref","unstructured":"Bele N, Darmon M, Coquet I, et al.: Diagnostic accuracy of procalcitonin in critically ill immunocompromised patients. BMC Infect Dis 2011; 11: 224","DOI":"10.1186\/1471-2334-11-224"},{"key":"10.3238\/arztebl.2015.0837_ref60","doi-asserted-by":"crossref","unstructured":"Otto G, Braconier J, Andreasson A, Svanborg C: Interleukin-6 and disease severity in patients with bacteremic and nonbacteremic febrile urinary tract infection. J Infect Dis 1999; 179: 172\u20139","DOI":"10.1086\/314534"},{"key":"10.3238\/arztebl.2015.0837_ref61","doi-asserted-by":"crossref","unstructured":"Lvovschi V, Arnaud L, Parizot C, et al.: Cytokine profiles in sepsis have limited relevance for stratifying patients in the emergency department: a prospective observational study. PLoS One 2011; 6: e28870.","DOI":"10.1371\/journal.pone.0028870"},{"key":"10.3238\/arztebl.2015.0837_ref62","doi-asserted-by":"crossref","unstructured":"Vincent JL, Beumier M: Diagnostic and prognostic markers in sepsis. Expert Rev Anti Infect Ther 2013; 11: 265\u201375","DOI":"10.1586\/eri.13.9"},{"key":"10.3238\/arztebl.2015.0837_ref63","doi-asserted-by":"crossref","unstructured":"Llewelyn M, Cohen J, International Sepsis F: Diagnosis of infection in sepsis. Intensive Care Med 2001; 27 (Suppl 1): S10\u201332 CrossRef","DOI":"10.1007\/PL00003792"},{"key":"10.3238\/arztebl.2015.0837_ref64","doi-asserted-by":"crossref","unstructured":"Brandt AS, Degener S, Lazica DA, Roth S: [Diagnostic puncture of the renal pelvis: avoidance of urinary diversion in cases of hydronephrosis and non-specific fever]. Urologe A 2012; 51: 1438\u201343","DOI":"10.1007\/s00120-012-2971-x"},{"key":"10.3238\/arztebl.2015.0837_ref65","doi-asserted-by":"crossref","unstructured":"Hoddick W, Jeffrey RB, Goldberg HI, Federle MP, Laing FC: CT and sonography of severe renal and perirenal infections. AJR Am J Roentgenol 1983; 140: 517\u201320","DOI":"10.2214\/ajr.140.3.517"},{"key":"10.3238\/arztebl.2015.0837_ref66","doi-asserted-by":"crossref","unstructured":"Wagenlehner FM, Pilatz A, Weidner W: Urosepsis--from the view of the urologist. Int J Antimicrob Agents 2011; 38 (Suppl): 51\u20137","DOI":"10.1016\/j.ijantimicag.2011.09.007"},{"key":"10.3238\/arztebl.2015.0837_ref67","doi-asserted-by":"crossref","unstructured":"Auinger K, Maggiorini M: Early, goal-directed resuscitation for septic shock. N Engl J Med 2015; 373: 576","DOI":"10.1056\/NEJMc1506514"},{"key":"10.3238\/arztebl.2015.0837_ref68","doi-asserted-by":"crossref","unstructured":"Roberts JA, Lipman J: Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006; 45: 755\u201373","DOI":"10.2165\/00003088-200645080-00001"},{"key":"10.3238\/arztebl.2015.0837_ref69","doi-asserted-by":"crossref","unstructured":"Brunkhorst FM, Oppert M, Marx G, et al.: Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA 2012; 307: 2390\u20139","DOI":"10.1001\/jama.2012.5833"},{"key":"10.3238\/arztebl.2015.0837_ref70","doi-asserted-by":"crossref","unstructured":"Lorente JA, Landin L, De Pablo R, Renes E, Rodriguez-Diaz R, Liste D: Effects of blood transfusion on oxygen transport variables in severe sepsis. Crit Care Med 1993; 21: 1312\u20138","DOI":"10.1097\/00003246-199309000-00013"},{"key":"10.3238\/arztebl.2015.0837_ref71","doi-asserted-by":"crossref","unstructured":"Annane D, Sebille V, Charpentier C, et al.: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862\u201371","DOI":"10.1001\/jama.288.7.862"},{"key":"10.3238\/arztebl.2015.0837_ref72","doi-asserted-by":"crossref","unstructured":"Briegel J, Forst H, Haller M, et al.: Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999; 27: 723\u201332","DOI":"10.1097\/00003246-199904000-00025"},{"key":"10.3238\/arztebl.2015.0837_ref73","doi-asserted-by":"crossref","unstructured":"Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26: 645\u201350","DOI":"10.1097\/00003246-199804000-00010"},{"key":"10.3238\/arztebl.2015.0837_ref74","doi-asserted-by":"crossref","unstructured":"Beale R, Janes JM, Brunkhorst FM, et al.: Global utilization of low-dose corticosteroids in severe sepsis and septic shock: a report from the PROGRESS registry. Crit Care 2010; 14: R102.","DOI":"10.1186\/cc9044"},{"key":"10.3238\/arztebl.2015.0837_ref75","doi-asserted-by":"crossref","unstructured":"Heyland DK: Selenium supplementation in critically ill patients: can too much of a good thing be a bad thing? Crit Care 2007; 11: 153","DOI":"10.1186\/cc5975"},{"key":"10.3238\/arztebl.2015.0837_ref76","doi-asserted-by":"crossref","unstructured":"Ranieri VM, Thompson BT, Barie PS, et al.: Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366: 2055\u201364","DOI":"10.1056\/NEJMoa1202290"},{"key":"10.3238\/arztebl.2015.0837_ref77","doi-asserted-by":"crossref","unstructured":"Hetz H, Berger R, Recknagel P, Steltzer H: Septic shock secondary to beta-hemolytic streptococcus-induced necrotizing fasciitis treated with a novel cytokine adsorption therapy. Int J Artif Organs 2014; 37: 422\u20136","DOI":"10.5301\/ijao.5000315"},{"key":"10.3238\/arztebl.2015.0837_ref78","doi-asserted-by":"crossref","unstructured":"Wiegele M, Krenn CG: Cytosorb in a patient with legionella pneumonia-associated rhabdomyolysis: a case report. ASAIO J 2015; 61: e14\u20136","DOI":"10.1097\/MAT.0000000000000197"},{"key":"10.3238\/arztebl.2015.0837_ref79","doi-asserted-by":"crossref","unstructured":"Puskarich MA, Trzeciak S, Shapiro NI, et al.: Outcomes of patients undergoing early sepsis resuscitation for cryptic shock compared with overt shock. Resuscitation 2011; 82: 1289\u201393","DOI":"10.1016\/j.resuscitation.2011.06.015"},{"key":"10.3238\/arztebl.2015.0837_ref80","doi-asserted-by":"crossref","unstructured":"Johansen TE, Cek M, Naber KG, et al.: Hospital acquired urinary tract infections in urology departments: pathogens, susceptibility and use of antibiotics. Data from the PEP and PEAP-studies. Int J Antimicrob Agents 2006; 28 (Suppl 1): S91\u2013107.","DOI":"10.1016\/j.ijantimicag.2006.05.005"},{"key":"10.3238\/arztebl.2015.0837_ref81","doi-asserted-by":"crossref","unstructured":"Bouza E, San Juan R, Munoz P, Voss A, Kluytmans J, Co-operative Group of the European Study Group on Nosocomial infection: A European perspective on nosocomial urinary tract infections II. Report on incidence, clinical characteristics and outcome (ESGNI-004 study). European Study Group on Nosocomial Infection. Clin Microbiol Infect 2001; 7: 532\u201342","DOI":"10.1046\/j.1198-743x.2001.00324.x"},{"key":"10.3238\/arztebl.2015.0837_ref82","doi-asserted-by":"crossref","unstructured":"Alhambra A, Cuadros JA, Cacho J, Gomez-Garces JL, Alos JI: In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J Antimicrob Chemother 2004; 53: 1090\u20134","DOI":"10.1093\/jac\/dkh218"},{"key":"10.3238\/arztebl.2015.0837_ref83","doi-asserted-by":"crossref","unstructured":"Reinhart K, Bauer M, Riedemann NC, Hartog CS: New approaches to sepsis: molecular diagnostics and biomarkers. Clin Microbiol Rev 2012; 25: 609\u201334","DOI":"10.1128\/CMR.00016-12"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2015.0837","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T09:17:28Z","timestamp":1638782248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2015.0837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,4]]},"references-count":83,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2015.0837","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,4]]}}}